Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 47, Issue 11

Issues

Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks

Altan Onat
  • Turkish Society of Cardiology, Istanbul, Turkey
  • Departments of Cardiology and Public Health, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gülay Hergenç / Erkan Ayhan / Murat Uğur / Günay Can
  • Departments of Cardiology and Public Health, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2009-10-12 | DOI: https://doi.org/10.1515/CCLM.2009.310

Abstract

Background: We evaluated prospectively the predictive value of serum apolipoprotein (apo) A-II, the second major apolipoprotein of high-density lipoprotein (HDL), for cardiometabolic risk in Turkish adults showing abnormalities in other proteins that normally confer protection.

Methods: Determinants of apoA-II and its associations with coronary heart disease (CHD), metabolic syndrome (MetS) and diabetes were investigated at 4 years follow-up in 193 elderly men and women.

Results: ApoA-II concentrations at baseline, in addition to being significantly related to HDL-cholesterol, were directly associated with complement C3 in multivariate linear regression analyses comprising nine variables. Following adjustment for gender, age and HDL-cholesterol (>30/>33 g/L, in men and women, respectively), low serum apoA-II concentrations predicted incident MetS [relative risk (RR) 3.5 (95% CI 1.4; 8.6)] and type 2 diabetes [RR 4.5 (95% CI 1.3; 15.6)] in both genders at an increment of 1 SD. Increased apoA-II values were not associated with prevalent or incident CHD, and tended to be marginally atheroprotective only in males.

Conclusions: Serum apoA-II concentrations confer risk for MetS and diabetes and exhibit evidence of anti-inflammatory properties among Turks. These findings support the effects seen for several other HDL protein constituents. This finding may explain the increased cardiometabolic risk among Turks.

Clin Chem Lab Med 2009;47:1389–94.

Keywords: apolipoprotein A-II; coronary heart disease; diabetes; metabolic syndrome; proinflammatory state

About the article

Corresponding author: Prof. Dr. Altan Onat, Nisbetiye cad. 59/24, Etiler 34335, İstanbul, Turkey Phone: +90 212 351 6217, Fax: +90 212 351 4235,


Received: 2009-06-18

Accepted: 2009-07-24

Published Online: 2009-10-12

Published in Print: 2009-11-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 47, Issue 11, Pages 1389–1394, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.310.

Export Citation

©2009 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Arkadiy V. Semke, Nikolay A. Bokhan, Anton J.M. Loonen, and Svetlana A. Ivanova
Heliyon, 2019, Volume 5, Number 7, Page e02033
[2]
Yun-Hsun Hsu, Jia-Jia Toh, Chiz-Tzung Chang, and Mine-Yine Liu
Journal of Chromatography A, 2019, Volume 1593, Page 164
[3]
Altan Onat, Aysem Kaya, and Evin Ademoglu
Expert Review of Cardiovascular Therapy, 2017, Page 1
[4]
Sun Min Kim, Joong Shin Park, Errol R. Norwitz, Seung Mi Lee, Byoung Jae Kim, Chan-Wook Park, Jong Kwan Jun, Chul-Woo Kim, and Hee Chul Syn
Reproductive Sciences, 2012, Volume 19, Number 2, Page 202
[5]
Sophia Morel, Jade Leahy, Maryse Fournier, Benoit Lamarche, Carole Garofalo, Guy Grimard, Floriane Poulain, Edgard Delvin, Caroline Laverdière, Maja Krajinovic, Simon Drouin, Daniel Sinnett, Valérie Marcil, and Emile Levy
Journal of Lipid Research, 2017, Volume 58, Number 5, Page 982
[6]
Altan Onat, Yusuf Karadeniz, Eyyup Tusun, Hüsniye Yüksel, and Ayşem Kaya
Expert Review of Cardiovascular Therapy, 2016, Volume 14, Number 4, Page 513
[7]
Fariba Koohdani, Haleh Sadrzadeh-Yeganeh, Mahmoud Djalali, Mohammadreza Eshraghian, Laleh Keramat, Mohammad-Ali Mansournia, and Elham Zamani
Journal of Diabetes and its Complications, 2015, Volume 29, Number 7, Page 908
[8]
Karina Fischer, Laura A. Da Costa, Bibiana García-Bailo, Christoph H. Borchers, and Ahmed El-Sohemy
Journal of Proteome Research, 2012, Volume 11, Number 10, Page 5022
[9]
A. Onat, G. Can, G. Hergenç, M. Uğur, and H. Yüksel
Nutrition, Metabolism and Cardiovascular Diseases, 2012, Volume 22, Number 8, Page 643
[10]
Dong Won Yi, Dong Wook Jeong, Sang Yeoup Lee, Seok Man Son, and Yang Ho Kang
Diabetes & Metabolism Journal, 2012, Volume 36, Number 1, Page 56
[11]
Michael J. Stuart and Bernhard T. Baune
Neuroscience & Biobehavioral Reviews, 2012, Volume 36, Number 1, Page 658
[13]
A Xue, C J Scarlett, L Chung, G Butturini, A Scarpa, R Gandy, S R Wilson, R C Baxter, and R C Smith
British Journal of Cancer, 2010, Volume 103, Number 3, Page 391

Comments (0)

Please log in or register to comment.
Log in